A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
A phase 3 trial testing QLS32015 in multiple myeloma, now recruiting.
Overview
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07138209, led by Qilu Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 228 participants (estimated). The study started in 2025-11-07 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Qilu Pharmaceutical and the tag ctgov-ingest.
- TrialA Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Shares Qilu Pharmaceutical and the tag ctgov-ingest.